| Deler fremragende | 35,126,884 shares |
| Insideraktier | 34.186.034 shares |
| Insider ejerskab | 97,32 % |
| Total Insiders | 31 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Skye Bioscience, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
|
5AM Partners VII, LLC
10% Owner -
|
8.224.699 | 8.224.699 | |
| Kaitlyn Melanie Arsenault Chief Financial Officer - [O] | 167.522 | 167.522 | |
| Elizabeth Berecz Chief Financial Officer - [O] | 1.050.000 | 1.050.000 | |
| Douglas A Cesario CFO and Secretary - [O] | 643.501 | 643.501 | |
| Margaret Dalesandro | 400.000 | ||
| Avtar S Dhillon Director - [D] | 0 | 0 | |
| Punit Dhillon Chief Executive Officer, Director - [D] [O] | 329.823 | 329.823 | |
| Tuan Tu Diep Chief Operating Officer - [O] | 4.000 | 4.000 | |
|
Emerald Health Sciences Inc.
10% Owner -
|
169.407.901 | 677.632 | |
| Thomas George Director - [D] | 60.000 | 60.000 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Grayson Paul A. Director - [D] | 259.701 | 259.701 | |
| James L Heppell Director - [D] | 500.000 | 500.000 | |
| John B Hollister | 200.000 | ||
| Douglas S Ingram Vice Chairman, Director - [D] [O] | 372.500 | 372.500 | |
| Richard Janney | 0 | ||
| Dennis D Kim | 4.736.541 | ||
|
Cosmas N Lykos
Chairman, Director, 10% Owner -
[D]
[O]
|
4.599.400 | 4.599.400 | |
|
Brian D Ladin
10% Owner -
|
249.098 | 249.098 | |
|
Reg Alexander Lapham
10% Owner -
|
3.787.500 | 3.787.500 | |
| Francisco Javier Mendez - | 0 | 0 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| McLaughlin Gerald W. Director - [D] | 61.250 | 61.250 | |
| Yosbani Mendez - | 2.440 | 2.440 | |
| Brian Stuart Murphy CEO, Chief Medical Officer, Director - [D] [O] | 1.275.000 | 1.275.000 | |
| Sukhwinder Singh Rai Director - [D] | 73.561 | 294 | |
|
Schwab Andrew J.
Director, 10% Owner -
[D]
|
8.224.699 | 8.224.699 | |
|
Squires Richard D.
10% Owner -
|
1.515.000 | 1.515.000 | |
| Praveen Tyle | 275.000 | ||
| Elena Traistaru | 1.000.000 | ||
| Christopher Twitty Chief Scientific Officer - [O] | 162.484 | 162.484 | |
|
Versant Ventures III, LLC
10% Owner -
|
504.872.726 | 2.019.491 | |
| Keith Wayne Ward | 250.000 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i SKYE / Skye Bioscience, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i SKYE / Skye Bioscience, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 3/A | Diep Tuan Tu | SKYE | Common Stock | D | 72.833 | ||||||||
| 2026-04-02 | 3/A | Diep Tuan Tu | SKYE | Common Stock | D | 4.000 | ||||||||
| 2025-08-22 | 2025-08-22 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3,4200 | -6.470 | -22 | 57.493 | ||||
| 2025-08-22 | 2025-08-22 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3,4200 | -163.979 | -561 | 1.457.064 | ||||
| 2025-08-22 | 2025-08-21 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3,5700 | -2.314 | -8 | 63.963 | ||||
| 2025-08-22 | 2025-08-21 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3,5700 | -58.642 | -209 | 1.621.043 | ||||
| 2025-08-22 | 2025-08-22 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3,4200 | -6.470 | -22 | 57.493 | ||||
| 2025-08-22 | 2025-08-22 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3,4200 | -163.979 | -561 | 1.457.064 | ||||
| 2025-08-22 | 2025-08-21 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3,5700 | -2.314 | -8 | 63.963 | ||||
| 2025-08-22 | 2025-08-21 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3,5700 | -58.642 | -209 | 1.621.043 | ||||
| 2025-04-25 | 3 | Twitty Christopher | SKYE | Common Stock | D | 81.242 | ||||||||
| 2025-02-28 | 2024-11-18 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 4,9900 | -43.026 | -215 | 167.522 | ||||
| 2025-02-28 | 2024-11-15 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 5,5500 | -190 | -1 | 210.548 | ||||
| 2024-11-20 | 2024-11-18 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 4,9900 | -19.489 | -97 | 82.259 | ||||
| 2024-11-20 | 2024-11-15 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 5,5500 | -85 | -0 | 101.748 | ||||
| 2024-11-19 | 2024-11-18 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 4,9900 | -43.206 | -216 | 166.342 | ||||
| 2024-11-19 | 2024-11-15 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 5,5500 | -190 | -1 | 209.548 | ||||
| 2024-11-19 | 2024-11-18 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 4,9900 | -82.546 | -412 | 329.823 | ||||
| 2024-11-19 | 2024-11-15 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 5,5500 | -364 | -2 | 412.369 | ||||
| 2024-11-19 | 2024-11-18 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 4,9900 | -86.244 | -430 | 259.701 | ||||
| 2024-11-19 | 2024-11-15 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 5,5500 | -307 | -2 | 345.945 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6,0600 | -79 | -0 | 66.277 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6,0600 | -2.000 | -12 | 1.679.685 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6,0600 | -11.758 | -71 | 8.167.206 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6,6000 | -1.440 | -10 | 66.356 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6,6000 | -36.504 | -241 | 1.681.685 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6,6000 | -214.556 | -1.416 | 8.178.964 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6,0600 | -79 | -0 | 66.277 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6,0600 | -2.000 | -12 | 1.679.685 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6,0600 | -11.758 | -71 | 8.167.206 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6,6000 | -1.440 | -10 | 66.356 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6,6000 | -36.504 | -241 | 1.681.685 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6,6000 | -214.556 | -1.416 | 8.178.964 | ||||
| 2024-08-27 | 2024-08-26 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 15.727 | 412.733 | ||||||
| 2024-03-15 | 2024-03-13 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 10,0000 | 450.000 | 4.500 | 8.393.520 | ||||
| 2024-03-15 | 2024-03-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 10,0000 | 450.000 | 4.500 | 8.393.520 | ||||
| 2024-03-04 | 2024-02-29 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 100.000 | 346.252 | ||||||
| 2024-03-04 | 2024-02-29 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 25.000 | 101.833 | ||||||
| 2024-03-04 | 2024-02-29 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 25.000 | 209.738 | ||||||
| 2024-03-04 | 2024-02-29 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 100.000 | 397.006 | ||||||
| 2024-03-01 | 2024-02-29 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 25.000 | 210.738 | ||||||
| 2024-03-01 | 2024-02-29 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 100.000 | 397.006 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 2,3100 | 5.206.074 | 12.026 | 7.943.520 | ||||
| 2024-02-02 | 2024-01-31 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 2,3100 | 5.206.074 | 12.026 | 7.943.520 | ||||
| 2023-11-06 | 2023-11-06 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 173.721 | 246.252 | ||||||
| 2023-11-06 | 2023-11-06 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 194.270 | 297.006 | ||||||
| 2023-11-06 | 2023-11-06 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 128.209 | 185.738 | ||||||
| 2023-08-31 | 2023-08-29 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0,0187 | 881.000 | 16 | 25.683.957 | ||||
| 2023-08-31 | 2023-08-28 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0,0171 | 110.000 | 2 | 24.802.957 | ||||
| 2023-08-31 | 2023-08-25 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 20.277.414 | 24.683.957 | ||||||
| 2023-08-31 | 2023-08-23 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0,0118 | 9.000 | 0 | 24.692.957 | ||||
| 2023-08-29 | 2023-08-29 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0,0187 | 881.000 | 16 | 41.554.828 | ||||
| 2023-08-29 | 2023-08-28 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0,0171 | 110.000 | 2 | 40.673.828 | ||||
| 2023-08-29 | 2023-08-25 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 20.277.414 | 40.554.828 | ||||||
| 2023-08-29 | 2023-08-23 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0,0118 | 9.000 | 0 | 40.563.828 | ||||
| 2023-08-29 | 2023-08-25 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 18.132.596 | 18.132.596 | ||||||
| 2023-08-29 | 2023-08-25 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 13.382.118 | 14.382.118 | ||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 16.948.799 | ||||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 429.546.911 | ||||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 684.361.447 | ||||||||
| 2023-08-28 | 3 | Versant Ventures III, LLC By Versant Venture Capital III, L.P. | SKYE | Common Stock | I | 498.978.878 | ||||||||
| 2023-08-28 | 3 | Versant Ventures III, LLC By Versant Side Fund III, L.P. | SKYE | Common Stock | I | 2.946.924 | ||||||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 0,0103 | 6.389.921 | 66 | 16.948.799 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 0,0103 | 161.944.872 | 1.668 | 429.546.911 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 0,0103 | 684.361.447 | 7.049 | 684.361.447 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 10.558.878 | 10.558.878 | ||||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 267.602.039 | 267.602.039 | ||||||
| 2023-03-17 | 2023-02-22 | 4 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0,0386 | 41.379.164 | 1.597 | 169.407.901 | ||||
| 2023-03-17 | 2023-02-22 | 4 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0,0170 | 16.641.486 | 283 | 128.028.737 | ||||
| 2022-11-15 | 2022-11-10 | 4 | DHILLON PUNIT Trust | SKYE | Common Stock | I | 2.335.721 | 2.335.721 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 1.406.543 | 4.406.543 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | Rai Sukhwinder Singh Shares held by wife of Reporting Person | SKYE | Common Stock | I | 73.561 | 73.561 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | Rai Sukhwinder Singh Trust | SKYE | Common Stock | I | 22.157 | 22.157 | ||||||
| 2022-01-31 | 2020-08-07 | 5 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0,1000 | -2.566.666 | -257 | 111.387.251 | ||||
| 2022-01-31 | 2019-03-29 | 5 | Emerald Health Sciences Inc. | SKYE | Multi Draw Credit Facility - T3 | D | 0,40 | 5.354.861 | 5.354.861 | |||||
| 2022-01-31 | 2019-03-29 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0,50 | 2.500.000 | 2.500.000 | |||||
| 2022-01-31 | 2019-02-01 | 5 | Emerald Health Sciences Inc. | SKYE | Multi Draw Credit Facility - T2 | D | 0,40 | 38.822 | 38.822 | |||||
| 2022-01-31 | 2019-02-01 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0,50 | 2.500.000 | 2.500.000 | |||||
| 2022-01-31 | 2018-11-01 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0,50 | 2.500.000 | 2.500.000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | DHILLON PUNIT | SKYE | Stock Option (Right to Buy) | D | 0,06 | 3.090.000 | 3.090.000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 2.000.000 | 3.000.000 | ||||||
| 2021-12-16 | 2021-12-14 | 4 | Arsenault Kaitlyn Melanie | SKYE | Stock Option (Right to Buy) | D | 0,06 | 1.770.000 | 1.770.000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 1.000.000 | 1.000.000 | ||||||
| 2021-12-16 | 2021-12-14 | 4 | Ward Keith Wayne | SKYE | Director Option Grant (Right to Buy) | D | 0,06 | 250.000 | 250.000 | |||||
| 2021-10-05 | 2021-10-04 | 4 | Arsenault Kaitlyn Melanie | SKYE | Employee Stock Option (Right to Buy) | D | 0,09 | 1.600.000 | 2.000.000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | DALESANDRO MARGARET | SKYE | Director Stock Option (Right to Buy) | D | 0,12 | 150.000 | 400.000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | HEPPELL JAMES L | SKYE | Director Stock Option (Right to Buy) | D | 0,12 | 150.000 | 1.350.000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | TYLE PRAVEEN | SKYE | Director Stock Option (Right to Buy) | D | 0,12 | 25.000 | 275.000 | |||||
| 2021-07-26 | 2021-07-22 | 4 | TYLE PRAVEEN | SKYE | Director Option Grant (Right to Buy) | D | 0,14 | 250.000 | 250.000 | |||||
| 2020-08-13 | 2020-08-07 | 4/A | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0,1000 | -2.566.666 | -257 | 123.923.501 | ||||
| 2020-08-12 | 2020-08-07 | 4 | DALESANDRO MARGARET | EMBI | Director Option Grant (Right to Buy) | D | 0,04 | 250.000 | 250.000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0,1000 | -3.000.000 | -300 | 123.490.167 | ||||
| 2020-08-11 | 2020-08-07 | 4 | Traistaru Elena | EMBI | Consultant Option Grant (Right to Buy) | D | 0,04 | 1.000.000 | 1.000.000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | KIM DENNIS D | EMBI | Employee Stock Option (Right to Buy) | D | 0,04 | 4.000.000 | 4.736.541 | |||||
| 2020-08-11 | 2020-08-07 | 4 | HEPPELL JAMES L | EMBI | Director Option Grant (Right to Buy) | D | 0,04 | 1.000.000 | 1.200.000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | HEPPELL JAMES L | EMBI | Common Stock | D | 0,1000 | 500.000 | 50 | 500.000 | ||||
| 2020-08-11 | 2020-08-07 | 4 | DHILLON PUNIT | EMBI | Employee Option Grant (Right to Buy) | D | 0,04 | 9.000.000 | 9.200.000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | DHILLON PUNIT | EMBI | Common Stock | D | 0,1000 | 1.000.000 | 100 | 1.000.000 | ||||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | 7% Convertible Debt | D | 0,40 | 0,4000 | -4.080.000 | -1.632 | 5.036.250 | |||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Warrant(Right to Buy) | D | 0,10 | 0,1000 | -40.800.000 | -4.080 | 0 | |||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 4.080.000,0000 | 40.800.000 | 166.464.000.000 | 126.490.167 | ||||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0,1000 | 40.800.000 | 4.080 | 126.490.167 | ||||
| 2019-08-23 | 2019-08-21 | 4 | KIM DENNIS D | EMBI | Employee Stock Options (Right to Buy) | D | 0,30 | 736.541 | 736.541 | |||||
| 2019-04-01 | 2019-03-29 | 4 | Emerald Health Sciences Inc. | EMBI | Warrant (Right to Buy) | D | 0,50 | 2.500.000 | 7.500.000 | |||||
| 2019-04-01 | 2019-03-29 | 4 | Emerald Health Sciences Inc. | EMBI | 7% Convertible Debt | D | 0,40 | 2.000.000,0000 | 2.000.000 | 4.000.000.000 | 6.000.000 | |||
| 2019-02-01 | 2019-02-01 | 4 | Emerald Health Sciences Inc. | NMUS | Warrant (Right to Buy) | D | 0,50 | 2.500.000 | 2.500.000 | |||||
| 2019-02-01 | 2019-02-01 | 4 | Emerald Health Sciences Inc. | NMUS | 7% Convertible Debt | D | 0,40 | 2.500.000 | ||||||
| 2018-12-28 | 2018-12-27 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 37.667 | 73.153.917 | ||||||
| 2018-11-01 | 2018-11-01 | 4 | Emerald Health Sciences Inc. | NMUS | Warrant (Right to Buy) | D | 0,50 | 2.500.000 | 2.500.000 | |||||
| 2018-11-01 | 2018-11-01 | 4 | Emerald Health Sciences Inc. | NMUS | 7% Convertible Debt | D | 0,40 | 2.500.000 | ||||||
| 2018-10-12 | 2018-10-10 | 4 | DHILLON AVTAR S | NMUS | Director Stock Option (Right to Buy) | D | 0,30 | 1.000.000 | 1.000.000 | |||||
| 2018-10-12 | 3 | DHILLON AVTAR S | NMUS | No securities are beneficially owned. | D | 0 | ||||||||
| 2018-10-12 | 2018-10-10 | 4 | DHILLON PUNIT | NMUS | Director Stock Option (Right to Buy) | D | 0,30 | 200.000 | 200.000 | |||||
| 2018-10-12 | 2018-10-10 | 4 | HEPPELL JAMES L | NMUS | Director Stock Option (Right to Buy) | D | 0,30 | 200.000 | 200.000 | |||||
| 2018-07-23 | 2018-07-23 | 4 | Cesario Douglas A | NMUS | Employee Stock Option (Right to Buy) | D | 0,24 | 1.195.073 | 1.195.073 | |||||
| 2018-07-23 | 2018-07-23 | 4 | Cesario Douglas A | NMUS | Common Stock | D | 643.501 | 643.501 | ||||||
| 2018-05-31 | 3 | Cesario Douglas A | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Series F Convertible Preferred Stock | D | 0,10 | -2.000 | 0 | |||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Series B Convertible Preferred Stock | D | 0,10 | -1.234 | 0 | |||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0,1000 | 20.000.000 | 2.000 | 73.116.250 | ||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0,1000 | 12.335.000 | 1.234 | 53.116.250 | ||||
| 2018-03-02 | 2018-01-24 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock Warrant (Right to Buy) | D | 0,00 | -1.781.250 | 0 | |||||
| 2018-03-02 | 2018-01-24 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0,0010 | 1.781.250 | 2 | 40.781.250 | ||||
| 2018-02-21 | 2018-02-16 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock Warrants (right to buy) | D | 0,10 | 20.400.000 | 20.400.000 | |||||
| 2018-02-21 | 2018-02-16 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 15.000.000 | 39.000.000 | ||||||
| 2018-01-29 | 3 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 48.000.000 | ||||||||
| 2018-01-29 | 3 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 48.000.000 | ||||||||
| 2018-01-23 | 3 | DHILLON PUNIT | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-01-23 | 3 | HEPPELL JAMES L | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-01-22 | 2018-01-18 | 4 | Berecz Elizabeth | NMUS | Common Stock | D | 700.000 | 1.050.000 | ||||||
| 2018-01-22 | 2018-01-18 | 4 | LYKOS COSMAS N | NMUS | Common Stock | D | 900.000 | 4.599.400 | ||||||
| 2018-01-22 | 2018-01-18 | 4 | Murphy Brian Stuart | NMUS | Common Stock | D | 900.000 | 1.275.000 | ||||||
| 2017-03-28 | 2017-03-13 | 4 | Lapham Reg Alexander | NMUS | Common Stock | D | 1,0000 | -119.700 | -120 | 3.787.500 | ||||
| 2015-10-22 | 2015-10-20 | 4 | Berecz Elizabeth | NMUS | Common Stock | D | 350.000 | 350.000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | Murphy Brian Stuart | NMUS | Common Stock | D | 375.000 | 375.000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | McLaughlin Gerald W. | NMUS | Common Stock | D | 30.000 | 61.250 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | LYKOS COSMAS N | NMUS | Common Stock | D | 325.000 | 3.699.400 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | GEORGE THOMAS | NMUS | Common Stock | D | 60.000 | 60.000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | INGRAM DOUGLAS S | NMUS | Common Stock | D | 60.000 | 372.500 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | McLaughlin Gerald W. | NMUS | Series A Preferred Stock | D | -10.000 | 0 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | McLaughlin Gerald W. | NMUS | Common Stock | D | 31.250 | 31.250 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | INGRAM DOUGLAS S | NMUS | Series A Preferred Stock | D | -100.000 | 0 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | INGRAM DOUGLAS S | NMUS | Common Stock | D | 312.500 | 312.500 | ||||||
| 2015-06-03 | 2015-06-01 | 4 | INGRAM DOUGLAS S | NMUS | Stock Option (Right to Buy) | D | 3,00 | 40.000 | 40.000 | |||||
| 2015-06-02 | 2015-05-29 | 4 | McLaughlin Gerald W. | NMUS | Common Stock Warrant (Right to Buy) | D | 5,00 | 2.000 | 2.000 | |||||
| 2015-06-02 | 2015-05-29 | 4 | McLaughlin Gerald W. | NMUS | Series A Preferred Stock | D | 2,50 | 2,5000 | 10.000 | 25 | 10.000 | |||
| 2015-04-16 | 3 | Squires Richard D. See Footnote #1 and #3 | NMUS | Common Stock | I | 1.515.000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. | NMUS | Common Stock | D | 2.985.000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. | NMUS | Common Stock | D | 2.985.000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. See Footnote #1 and #3 | NMUS | Common Stock | I | 1.515.000 | ||||||||
| 2015-04-10 | 2015-04-10 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4,9290 | -11.830 | -58 | 249.098 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4,7900 | -15.800 | -76 | 260.928 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4,6910 | -23.000 | -108 | 276.728 | ||||
| 2015-01-12 | 2015-01-09 | 4 | GEORGE THOMAS | NMUS | Stock Option (Right to Buy) | D | 3,00 | 40.000 | 40.000 | |||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (4) | NMUS | Common Stock | I | 1.423.907 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (4) | NMUS | Common Stock | I | 1.423.907 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (3) | NMUS | Common Stock | I | 1.560.541 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (2) | NMUS | Common Stock | I | 1.394.268 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (3) | NMUS | Common Stock | I | 1.560.541 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (2) | NMUS | Common Stock | I | 1.394.268 | ||||||||
| 2014-12-08 | 2014-12-04 | 4 | McLaughlin Gerald W. | NMUS | Stock Option (Right to Buy) | D | 0,42 | 20.000 | 20.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | LYKOS COSMAS N | NMUS | Stock Option (Right to Buy) | D | 0,42 | 125.000 | 125.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Hollister John B | NMUS | Stock Option (Right to Buy) | D | 0,42 | 200.000 | 200.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Hollister John B | NMUS | Stock Option (Right to Buy) | D | 0,42 | 480.000 | 480.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Berecz Elizabeth | NMUS | Stock Option (Right to Buy) | D | 0,42 | 150.000 | 150.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Berecz Elizabeth | NMUS | Stock Option (Right to Buy) | D | 0,42 | 100.000 | 100.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Murphy Brian Stuart | NMUS | Stock Option (Right to Buy) | D | 0,42 | 175.000 | 175.000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Murphy Brian Stuart | NMUS | Stock Option (Right to Buy) | D | 0,42 | 480.000 | 480.000 | |||||
| 2014-11-10 | 2014-10-31 | 4/A | MENDEZ FRANCISCO JAVIER | LGLRD | Common Stock | D | -1.180.000 | 0 | ||||||
| 2014-11-10 | 3 | Lapham Reg Alexander | LGLRD | Common Stock | D | 7.814.400 | ||||||||
| 2014-11-10 | 3 | Lapham Reg Alexander | LGLRD | Common Stock | D | 7.814.400 | ||||||||
| 2014-11-10 | 3 | LYKOS COSMAS N | LGLRD | Common Stock | D | 6.748.800 | ||||||||
| 2014-11-10 | 3 | LYKOS COSMAS N | LGLRD | Common Stock | D | 6.748.800 | ||||||||
| 2014-11-10 | 2014-10-31 | 4 | Mendez Yosbani | LGLRD | Common Stock | D | -4.251.460 | 2.440 | ||||||
| 2014-11-10 | 2014-10-31 | 4 | MENDEZ FRANCISCO JAVIER | LGLR | Common Stock | D | -500.000 | 0 | ||||||
| 2014-01-29 | 3 | Mendez Yosbani | N/A | Common Stock | D | 1.802.500 | ||||||||
| 2014-01-29 | 3 | MENDEZ FRANCISCO JAVIER | N/A | Common Stock | D | 500.000 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
